Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Osteosarcoma
Stage/Subtype:  metastatic osteosarcoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 25 for your search:
Start Over
Hypofractionated or Single Dose Image-Guided Radiation Therapy in Treating Patients with Metastatic Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 10-154, NCI-2010-02150, NCT01223248
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Aerosolized Aldesleukin in Treating Patients with Lung Metastases
Phase: Phase II, Phase I
Type: Treatment
Age: 12 and over
Trial IDs: 2010-0700, NCI-2012-00788, NCT01590069
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Phase: Phase II, Phase I
Type: Treatment
Age: 15 and over
Trial IDs: 2012-0952, NCI-2013-02267, ONC-2012-66, NCT01833520
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 moths to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 and over
Trial IDs: AWACMOS1102, NCI-2013-01371, ACORN AWACMOS1102, NCT01759303
Hypofractionated Stereotactic Radiation Therapy in Treating Younger Patients with Metastatic Sarcomas of Bony Sites
Phase: Phase II
Type: Treatment
Age: Greater than 3 to less than or equal to 40
Trial IDs: J1367, NCI-2013-02433, NA_00070109, NCT01763970
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NA_00076243 / CIR00009228, NCT01804634
Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients with Metastatic Sarcoma Stable on Chemotherapy
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201309108, NCI-2013-01842, NCT01986829
A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC024, NCI-2014-02023, NCT02048371
A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Phase: Phase II
Type: Treatment
Age: 12 and over
Trial IDs: SARC028, NCI-2015-00320, NCT02301039
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients with Metastatic Soft Tissue and Bone Sarcomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14S03, NCI-2014-02583, STU00200112, NCT02357810
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, REN13120042, UPCI #10-027, NCT01345539
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
HER2-Specific T Cells in Treating Patients With HER2-Positive Refractory or Metastatic Sarcoma
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: HEROS, NCI-2012-00634, NCT00902044
Valproic Acid, Bevacizumab, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Locally Advanced, Unresectable, or Metastatic Sarcoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 200911736, NCI-2011-01092, AVF4761s, NCT01106872
Dasatinib and Ipilimumab in Treating Patients with Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-083, NCI-2012-01165, CDR0000737378, 9172, NCT01643278
Monoclonal Antibody 3F8 and Aldesleukin in Treating Patients with High-Risk Neuroblastoma and Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months and over
Trial IDs: 12-116, NCI-2012-01383, NCT01662804
T Cell Receptor Gene Therapy in Treating Younger Patients with Solid Tumors
Phase: Phase I
Type: Treatment
Age: 35 and under
Trial IDs: 14-C-0059, NCI-2014-02506, P131369, NCT02107963
Simvastatin, Topotecan Hydrochloride, and Cyclophosphamide in Treating Younger Patients with Relapsed and/or Refractory Solid and CNS Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 29
Trial IDs: AFLACST1402, NCI-2015-00420, IRB00078790, NCT02390843
Proton Beam Radiation Therapy in Treating Younger Patients with Bone or Non-rhabdomyosarcoma Soft Tissue Sarcomas
Phase: No phase specified
Type: Treatment
Age: 30 and under
Trial IDs: 05-326, NCI-2012-00673, NCT00592293
Prolonged Duration Methotrexate, Doxorubicin Hydrochloride, and Cisplatin with or without Pantoprazole Sodium in Reducing or Preventing Chemotherapy Induced Kidney Damage and Hearing Loss in Younger Patients with Previously Untreated Osteosarcoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 1 to 29
Trial IDs: CHP12ST051, NCI-2014-01661, 12ST051, 13-009967, CHP12ST051 OS Pilot, NCT01848457
External Beam Radiation Therapy and 153Sm-EDTMP in Treating Patients with High-Risk Bone Cancer That Is Metastatic or Cannot Be Removed by Surgery
Phase: No phase specified
Type: Treatment
Age: 13 to 65
Trial IDs: J1322, NCI-2013-01600, NA_00075773 / CIR00008887, NCT01886105
Effect of Radiation on Bone in Patients with Cancer of the Sacrum
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 14-208, NCI-2015-00893, NCT02323295
Start Over